1263 related articles for article (PubMed ID: 23456653)
1. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
2. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.
Looney RJ
Drugs; 2010 Mar; 70(5):529-40. PubMed ID: 20297867
[TBL] [Abstract][Full Text] [Related]
3. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
4. B-cell-targeted therapy for systemic lupus erythematosus: an update.
Ding C; Foote S; Jones G
BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
[TBL] [Abstract][Full Text] [Related]
5. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
[TBL] [Abstract][Full Text] [Related]
9. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.
Oon S; Huq M; Godfrey T; Nikpour M
Semin Arthritis Rheum; 2018 Oct; 48(2):221-239. PubMed ID: 29426575
[TBL] [Abstract][Full Text] [Related]
10. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
Hui-Yuen JS; Nguyen SC; Askanase AD
Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
[TBL] [Abstract][Full Text] [Related]
11. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
12. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
Terrier B; Mouthon L
Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
[TBL] [Abstract][Full Text] [Related]
13. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
15. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
Gualtierotti R; Borghi MO; Gerosa M; Schioppo T; Larghi P; Geginat J; Meroni PL
Clin Exp Rheumatol; 2018; 36(4):643-647. PubMed ID: 29533753
[TBL] [Abstract][Full Text] [Related]
16. Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D; Gordon C
Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
[TBL] [Abstract][Full Text] [Related]
17. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
18. B-cell-depleting therapy in systemic lupus erythematosus.
Ramos-Casals M; Sanz I; Bosch X; Stone JH; Khamashta MA
Am J Med; 2012 Apr; 125(4):327-36. PubMed ID: 22444096
[TBL] [Abstract][Full Text] [Related]
19. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C;
Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
